首页> 外文OA文献 >Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label , Phase Ib Study

【2h】

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label , Phase Ib Study

机译：Ramucirumab与Folfox4在晚期肝细胞癌患者中的安全性和初步疗效：非扫描，开放标签，相IB研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chia‐Chi Lin; Tsai‐Sheng Yang; Chia‐Jui Yen; Rebecca Cheng; Junjun Liu; Chiun Hsu;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study [J] . Chia-Chi Lin, Tsai-Sheng Yang, Chia-Jui Yen, The oncologist . 2020,第12期

机译：Ramucirumab与Folfox4在晚期肝细胞癌患者中的安全性和初步疗效：非扫描，开放标签，相IB研究
2. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study [J] . Vichien SRIMUNINNIMIT, Virote SRIURANPONG Suthida SUWANVECHO Asia-Pacific journal of clinical oncology . 2014,第3期

机译：索拉非尼联合吉西他滨治疗晚期肝细胞癌的疗效和安全性：一项多中心，开放标签，单组II期研究
3. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. [J] . Thomas A, Trarbach T, Bartel C, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第4期

机译：IB期开放标签剂量递增研究对晚期大肠癌患者的口服血管生成抑制剂PTK787 / ZK 222584（PTK / ZK）联合FOLFOX4化疗。
4. Preliminary study of CyberKnife in combination with CIK in reducing the short-term recurrence rates of hepatocellular carcinomas [C] . Guiqing Yang, Hanchen Liu, Xiaoxu Liu, International Conference on Human Health and Medical Engineering. . 2014

机译：Cik术与CIK结合减少肝细胞癌短期复发率的Cyber Knife初步研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase Ib Study of Safety and Pharmacokinetics of Ramucirumab in Combination With Paclitaxel in Patients With Advanced Gastric Adenocarcinomas [O] . Shinya Ueda, Taroh Satoh, Masahiro Gotoh, 2015

机译：Ib期研究：雷珠单抗联合紫杉醇治疗晚期胃腺癌的安全性和药代动力学
7. Efficacy and safety of sorafenib–gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study [O] . Naqi Naeem, Ahmad Shaharyar, Murad Sohail, 2014

机译：索拉非尼-吉西他滨联合疗法在晚期肝细胞癌中的疗效和安全性：开放标签的II期可行性研究

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label , Phase Ib Study

著录项

引文网络

相似文献

相关主题

期刊订阅